ADB-BINACA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products.[1] It was originally developed by Pfizer as a potential analgesic.
The analogue with a 1-butyl substitution on the indazole ring rather than 1-benzyl has also been sold as a designer drug under the name ADB-BINACA, but is now more commonly referred to as ADB-BUTINACA to avoid confusion with the benzyl compound.
Samples containing ADB-BUTINACA were detected across three jurisdictions in Massachusetts (Boston, Revere & Lawrence) from April 2021 to August 2021. The samples were sold as dope/heroin/fentanyl or Xanax bars. Nearly all contained fentanyl and 4-fluorofentanyl, a potent fentanyl analogue. ADB-BUTINACA is manufactured in clandestine laboratories and is not cut or packaged in a standard fashion. Potency varies widely for the end user.